TheraSense buy leads Abbott to cut MediSense jobs:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories' $1.1bn acquisition of blood glucose monitoring specialist TheraSense will result in the loss of around 400 jobs in Bedford, Massachusetts, where Abbott's existing diabetes outfit, MediSense, is based. The company intends to move all its diabetes monitoring operations to Alameda, California, where TheraSense is based. About 100 of the 500 MediSense staff will be offered alternative employment; the rest will receive severance or retirement packages. Abbott Park, Illinois-based Abbott intends to establish a new division, Abbott Diabetes Care, which will be headed by Ed Fiorentino, current president of MediSense.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.